Watch OLMA. Know when insiders buy.
One email the day a filing lands. Free.
OLMA
Olema Pharmaceuticals, Inc.
9.04
+0.21 +2.38%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $791MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$204.6MNET CASH —52W 7.77 – 35.83SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$67.2M | −$63.2M | — | -0.61 | −$45.9M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$58M | −$53.1M | — | -0.52 | −$46M | — | — | May 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$50.1M | −$46.1M | — | -0.51 | −$38.3M | — | — | Mar 16 |
| Q3 2025 · Sep 30 | — | — | — | −$45.9M | −$42.2M | — | -0.49 | −$34.5M | $0 | −$34.5M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$47.9M | −$43.8M | — | -0.51 | −$29.9M | — | — | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$34.9M | −$30.4M | — | -0.36 | −$44M | — | — | May 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$36.8M | −$33.6M | — | -0.40 | −$26.3M | $0 | −$26.3M | Mar 16 |
| Q3 2024 · Sep 30 | — | — | — | −$37.6M | −$34.6M | — | -0.60 | −$27M | $0 | −$27M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$33.5M | −$30.4M | — | -0.54 | −$27.6M | $6K | −$27.6M | Aug 11 |
| Q1 2024 · Mar 31 | — | — | — | −$34.3M | −$31M | — | -0.56 | −$23.5M | $153K | −$23.6M | May 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$30.4M | −$26.8M | — | -0.48 | −$18.5M | — | — | Mar 18 |
| Q3 2023 · Sep 30 | — | — | — | −$23.3M | −$21.5M | — | -0.48 | −$22.7M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$178.7M | −$162.5M | — | -1.87 | −$146.7M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$142.3M | −$129.5M | — | -2.20 | −$104.4M | $159K | −$104.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$105M | −$96.7M | — | -2.14 | −$83.7M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$107M | −$104.8M | — | -2.62 | −$82.1M | $363K | −$82.4M | — | — |
| FY2021 · to Dec 31 | — | — | −$71.5M | −$71.1M | — | -1.80 | −$50.7M | $1.6M | −$52.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$21.5M | −$22.1M | — | -3.42 | −$19.9M | $56K | −$19.9M | — | — |
Every number comes from Olema Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.